{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:34:16Z","timestamp":1792805656008,"version":"4.5.0"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.2215\/cjn.00580118","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:35:28Z","timestamp":1529321728000},"page":"1738-1746","source":"Crossref","is-referenced-by-count":103,"title":["Medication Safety Principles and Practice in CKD"],"prefix":"10.2215","volume":"13","author":[{"given":"Chanel F.","family":"Whittaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Miklich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"B1-20230601","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/00325481.1978.11714978","article-title":"Drug use in renal failure","volume":"64","author":"Henrich","year":"1978","journal-title":"Postgrad Med"},{"key":"B2-20230601","first-page":"259","article-title":"The use of drugs in renal failure","volume":"6","author":"Reed","year":"1986","journal-title":"Semin Nephrol"},{"key":"B3-20230601","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1681\/ASN.2005020192","article-title":"Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: Evidence for lack of physician awareness of chronic kidney disease","volume":"16","author":"Stevens","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230601","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1681\/ASN.2004070539","article-title":"Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000","volume":"16","author":"Coresh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230601","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.286.22.2839","article-title":"Guided medication dosing for inpatients with renal insufficiency","volume":"286","author":"Chertow","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 1","key":"B6-20230601","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/11534640-000000000-00000","article-title":"Potentially inappropriate medication in elderly hospitalized patients","volume":"26","author":"Corsonello","year":"2009","journal-title":"Drugs Aging"},{"key":"B7-20230601","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1093\/ndt\/gfl399","article-title":"Use of renal risk drugs in hospitalized patients with impaired renal function--an underestimated problem?","volume":"21","author":"Blix","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B8-20230601","first-page":"23","article-title":"Prescribing principles for patients with chronic kidney disease","volume":"18","author":"Brown","year":"2008","journal-title":"Pharm Pract (Granada)"},{"key":"B9-20230601","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","article-title":"Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Matzke","year":"2011","journal-title":"Kidney Int"},{"key":"B10-20230601","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","article-title":"Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations","volume":"54","author":"Stevens","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B11-20230601","first-page":"473","article-title":"Nephrology: 3. Safe drug prescribing for patients with renal insufficiency","volume":"166","author":"Kappel","year":"2002","journal-title":"CMAJ"},{"key":"B12-20230601","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MNH.0b013e3283136732","article-title":"Altered nonrenal drug clearance in ESRD","volume":"17","author":"Nolin","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B13-20230601","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"key":"B14-20230601","first-page":"557","article-title":"Metabolic and adverse effects of diuretics","volume":"19","author":"Wilcox","year":"1999","journal-title":"Semin Nephrol"},{"key":"B15-20230601","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","article-title":"Metabolic complications associated with use of diuretics","volume":"31","author":"Palmer","year":"2011","journal-title":"Semin Nephrol"},{"key":"B16-20230601","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"B17-20230601","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"B18-20230601","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1093\/ndt\/gfp357","article-title":"Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4","volume":"24","author":"Tomlinson","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230601","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis","volume":"115","author":"Toto","year":"1991","journal-title":"Ann Intern Med"},{"key":"B20-20230601","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-106-3-346","article-title":"Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure","volume":"106","author":"Packer","year":"1987","journal-title":"Ann Intern Med"},{"key":"B21-20230601","doi-asserted-by":"crossref","first-page":"e8525","DOI":"10.1136\/bmj.e8525","article-title":"Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study","volume":"346","author":"Lapi","year":"2013","journal-title":"BMJ"},{"key":"B22-20230601","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: Potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B23-20230601","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.03470316","article-title":"Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade","volume":"11","author":"Palevsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24-20230601","doi-asserted-by":"crossref","first-page":"e78465","DOI":"10.1371\/journal.pone.0078465","article-title":"ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: A longitudinal ecological study","volume":"8","author":"Tomlinson","year":"2013","journal-title":"PLoS One"},{"key":"B25-20230601","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B26-20230601","article-title":"Association of QT-prolonging medication use in CKD with electrocardiographic manifestations [published online ahead of print August 9, 2017]","author":"Snitker","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27-20230601","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B28-20230601","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B29-20230601","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"B30-20230601","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"B31-20230601","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2215\/CJN.12411213","article-title":"Serum potassium in dual renin-angiotensin-aldosterone system blockade","volume":"9","author":"Seliger","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B32-20230601","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0002-9343(99)80017-5","article-title":"Heparin-induced aldosterone suppression and hyperkalemia","volume":"98","author":"Oster","year":"1995","journal-title":"Am J Med"},{"key":"B33-20230601","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jash.2017.09.011","article-title":"Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension","volume":"11","author":"Kovesdy","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"B34-20230601","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","article-title":"Treatment of hyperkalemia: Something old, something new","volume":"89","author":"Sterns","year":"2016","journal-title":"Kidney Int"},{"key":"B35-20230601","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.ajkd.2012.04.023","article-title":"Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: A retrospective cohort study","volume":"60","author":"Watson","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B36-20230601","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"B37-20230601","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/j.ajkd.2016.01.001","article-title":"Patiromer for hyperkalemia in diabetic CKD: A new kid on the block","volume":"67","author":"Garimella","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B38-20230601","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1093\/ndt\/gfm386","article-title":"Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis","volume":"22","author":"Kim","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B39-20230601","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B40-20230601","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B41-20230601","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/ki.2008.299","article-title":"Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"74","author":"Locatelli","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"B42-20230601","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-6686.2009.00125.x","article-title":"Iron therapy in chronic kidney disease: Current controversies","volume":"35","author":"Kovesdy","year":"2009","journal-title":"J Ren Care"},{"key":"B43-20230601","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B44-20230601","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1185\/03007990903512461","article-title":"Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous?","volume":"26","author":"Macdougall","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B45-20230601","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3121\/cmr.2008.811","article-title":"Safety issues with intravenous iron products in the management of anemia in chronic kidney disease","volume":"6","author":"Hayat","year":"2008","journal-title":"Clin Med Res"},{"key":"B46-20230601","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMe068233","article-title":"Correction of anemia--payoffs and problems","volume":"355","author":"Remuzzi","year":"2006","journal-title":"N Engl J Med"},{"key":"B47-20230601","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B48-20230601","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B49-20230601","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"B50-20230601","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ndt\/gfq099","article-title":"Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA)","volume":"25","author":"Goldsmith","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"B51-20230601","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B52-20230601","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2215\/CJN.04970512","article-title":"Critical and honest conversations: The evidence behind the \u201cChoosing Wisely\u201d campaign recommendations by the American Society of Nephrology","volume":"7","author":"Williams","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B53-20230601","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"B54-20230601","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2369-14-14","article-title":"Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients","volume":"14","author":"Chartsrisak","year":"2013","journal-title":"BMC Nephrol"},{"key":"B55-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B56-20230601","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B57-20230601","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2014.425","article-title":"Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference","volume":"87","author":"Ketteler","year":"2015","journal-title":"Kidney Int"},{"key":"B58-20230601","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"B59-20230601","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11914-017-0368-x","article-title":"Calcium balance in chronic kidney disease","volume":"15","author":"Hill Gallant","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"B60-20230601","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"B61-20230601","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MNH.0000000000000317","article-title":"Anemia management in chronic kidney disease and dialysis: A narrative review","volume":"26","author":"Collister","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 2","key":"B62-20230601","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/nep.13026","article-title":"Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?","volume":"22","author":"Toussaint","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"B63-20230601","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2165\/00003495-200767140-00002","article-title":"Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: Understanding the differences among therapies","volume":"67","author":"Brancaccio","year":"2007","journal-title":"Drugs"},{"key":"B64-20230601","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey","year":"2014","journal-title":"BMC Res Notes"},{"issue":"Suppl 1","key":"B65-20230601","first-page":"S4","article-title":"Standards of medical care in diabetes-2017: Summary of revisions","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"B66-20230601","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"B68-20230601","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B69-20230601","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000380974","article-title":"DPP-4 inhibitors in diabetic patients with chronic kidney disease and end-stage kidney disease on dialysis in clinical practice","volume":"185","author":"Abe","year":"2015","journal-title":"Contrib Nephrol"},{"key":"B70-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-014-0198-2","article-title":"Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"B71-20230601","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"key":"B72-20230601","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"B73-20230601","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"B74-20230601","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2042018816676239","article-title":"The renal effects of SGLT2 inhibitors and a mini-review of the literature","volume":"7","author":"Andrianesis","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B75-20230601","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40842-015-0001-9","article-title":"Management of diabetes mellitus in patients with chronic kidney disease","volume":"1","author":"Hahr","year":"2015","journal-title":"Clin Diabetes Endocrinol"},{"key":"B76-20230601","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B77-20230601","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"B78-20230601","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.00500107","article-title":"A review of dietary supplement-induced renal dysfunction","volume":"2","author":"Gabardi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B79-20230601","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: The process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B80-20230601","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1592\/phco.29.12.1433","article-title":"Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: A 2-year, randomized, controlled study","volume":"29","author":"Pai","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B81-20230601","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2017.02.374","article-title":"Targeted deprescribing in an outpatient hemodialysis unit: A quality improvement study to decrease polypharmacy","volume":"70","author":"McIntyre","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B82-20230601","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/aje\/kwj331","article-title":"Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis","volume":"164","author":"Schneider","year":"2006","journal-title":"Am J Epidemiol"},{"key":"B83-20230601","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B84-20230601","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.2215\/CJN.01420213","article-title":"Medication reconciliation and therapy management in dialysis-dependent patients: Need for a systematic approach","volume":"8","author":"Pai","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B85-20230601","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/MNH.0b013e328365b364","article-title":"New models of chronic kidney disease care including pharmacists: Improving medication reconciliation and medication management","volume":"22","author":"St Peter","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201811000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:02Z","timestamp":1786369082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201811000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00580118","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]}}}